TL;DR
This paper presents a new class of quinazoline-based compounds showing promising activity against Schistosoma mansoni, the parasite causing schistosomiasis. By combining in vivo studies, medicinal chemistry, and computational approaches, the researchers identified aldose reductase as the likely enzymatic target, paving the way for developing improved treatments for this neglected tropical disease.
What Problem Does This Paper Address?
Schistosomiasis remains a significant global health burden, particularly in tropical and subtropical regions. Current treatment relies heavily on praziquantel (PZQ), but concerns about potential therapeutic failure and the emergence of resistance necessitate the development of new antischistosomal drugs. Historically, drug discovery for schistosomiasis has relied on phenotypic screening (observing effects on the whole organism). While effective, this approach often lacks a clear understanding of the drug's mechanism of action (MOA), which is crucial for anticipating and overcoming resistance. This paper aims to address this by identifying a novel class of antischistosomal agents, optimizing their properties, and, importantly, deciphering their molecular target using a combination of experimental and computational methods.
Methods
The study employed a multi-pronged approach:
- In Vivo Efficacy Studies: The lead compound, NPD-1246, was tested in a mouse model infected with Schistosoma mansoni. This involved assessing its ability to reduce worm burden and egg load, both alone and in combination with PZQ, and with the co-administration of a CYP450 inhibitor (ABT) to mitigate metabolic degradation.
- Medicinal Chemistry: To improve the drug-like properties, particularly metabolic stability, of NPD-1246, a series of derivatives were synthesized. This involved modifying specific positions on the quinazoline scaffold predicted to be susceptible to metabolic breakdown.
- Metabolic Stability Assays: The metabolic stability of the parent compound and its derivatives was assessed using mouse and human liver microsomes to evaluate their susceptibility to phase-I (e.g., CYP450) and phase-II (e.g., UGT) metabolism.
- Computational Target Deconvolution: A key aspect of this research was identifying the molecular target. This was achieved through a consensus approach using three complementary in silico methodologies:
- Polypharmacology Browser (PPB): Used for ligand similarity-based target prediction.
- Similarity Ensemble Approach (SEA): Another method for identifying potential targets based on chemical similarity to known compounds.
- Protein Data Bank (PDB) Search: A structural comparison to identify known quinazoline-bound protein structures.
- Homology Modeling: Since a crystal structure for Schistosoma mansoni aldose reductase was unavailable, a homology model was built using the structure of S. japonicum aldose reductase as a template.
- Docking Studies: The binding mode of NPD-1246 and its promising derivatives (compounds 9 and 10) to the modeled S. mansoni aldose reductase was investigated using docking simulations to understand their interaction with the enzyme's active site.
Datasets
- Biological Data: In vitro and in vivo efficacy data for NPD-1246 and its derivatives against Schistosoma mansoni.
- Metabolic Stability Data: Percentage of parent compound remaining over time in the presence of mouse and human liver microsomes.
- Computational Databases:
- ChEMBL and PubChem were implicitly used as sources for the computational target prediction tools.
- Protein Data Bank (PDB) was used to retrieve crystal structures for homology modeling and docking validation.
- Newly Introduced Benchmarks: Not explicitly introduced as new benchmarks, but the study generated new in vitro and in vivo efficacy data for a novel series of quinazoline compounds.
Key Insights and Ideas
- Synergistic Effect with PZQ: Combining the new quinazoline derivative NPD-1246 with PZQ showed a significant synergistic effect, leading to a much higher reduction in worm burden and a complete disappearance of immature eggs, which are crucial for disease transmission.
- Metabolic Instability of NPD-1246: The parent compound NPD-1246 was found to be rapidly metabolized by phase-I enzymes, limiting its potential for in vivo efficacy. This highlighted the need for medicinal chemistry optimization.
- Successful Derivatization: Medicinal chemistry efforts successfully yielded derivatives (compounds 9 and 10) with improved metabolic stability while retaining significant antischistosomal activity.
- Aldose Reductase as a Promising Target: The convergence of three different computational target prediction methods pointed towards aldose reductase as the likely molecular target for this class of quinazoline compounds. This is a significant finding as it provides a specific molecular basis for their action.
- Aromatic Interactions Drive Binding: Docking studies revealed that NPD-1246 and its derivatives bind to the catalytic site of aldose reductase through key aromatic interactions with residues like Tyr207, His110, Trp111, and Phe293, explaining their inhibitory potential.
Key Results
- In Vivo Efficacy: NPD-1246 at 20 mg/kg showed a modest reduction in worm burden (24%) and egg load (18%). However, when combined with PZQ (10 mg/kg each), it achieved an 80% reduction in worm burden and complete elimination of immature eggs.
- Metabolic Stability: NPD-1246 was poorly metabolically stable, with only 27% remaining after 30 minutes in mouse microsomes. Derivatives 9 and 10 showed significantly improved stability, with 51% and 39% remaining, respectively, after 30 minutes in mouse microsomes.
- In Vitro Activity: Compounds 9 and 10 demonstrated potent in vitro activity against S. mansoni worms, with EC50 values comparable to or better than NPD-1246 (EC50 of 47 µM for compound 9 and 25 µM for compound 10, compared to 50 µM for NPD-1246).
- Target Identification: Computational analysis strongly suggested aldose reductase as the molecular target for the quinazoline compounds.
- Binding Mode: Docking studies predicted a stable binding mode of NPD-1246 within the active site of S. mansoni aldose reductase, driven by aromatic interactions.
Limitations and Future Work
- Metabolic Stability of Parent Compound: The primary limitation of the parent compound NPD-1246 was its poor metabolic stability, which was addressed through medicinal chemistry.
- Homology Model: The study relied on a homology model for S. mansoni aldose reductase, as its crystal structure was not available. While validated, direct experimental confirmation of the binding mode with the actual S. mansoni enzyme would be ideal.
- Further In Vivo Studies: While promising, the in vivo studies were conducted in a mouse model. Further evaluation in other relevant animal models and ultimately in human clinical trials would be necessary.
- Mechanism of Action Confirmation: While aldose reductase is proposed as the target, further experimental validation of this hypothesis (e.g., enzyme inhibition assays with purified S. mansoni aldose reductase) would strengthen the findings.
- Drug-like Properties: While metabolic stability was improved, a comprehensive assessment of other drug-like properties (e.g., solubility, bioavailability, toxicity) for the optimized derivatives would be crucial for further development.
The authors suggest that the identified quinazoline derivatives, particularly compounds 9 and 10, represent promising candidates for further evaluation and development as antischistosomal agents, with aldose reductase emerging as a novel and important therapeutic target.
Summary updated